Neurologic diseases and neurogenetics
PRINCIPAL INVESTIGATORS
- Helena Bejr-Kasem Marco
- Serge Jauma Classen
- Monica Povedano Panades
- Joan Prat Rojo
- Sergio Martínez Yélamos
- Jordi Gascon Bayarri
- Cristina Sanchez Castañeda
- Lucía Aja Rodríguez
- Mariano Huerta Villanueva
- Matilde Calopa Garriga
- Pere Cardona Portela
- Mercè Falip Centellas
- Julia Miró Lladó
CLINICAL RESEARCHERS
- Laura Bau Vila
- Elisabet Matas Martín
- Pere Domènech Santasusana
- Misericordia Veciana Veciana De Las Heras
- Lucia Maria Romero Pinel
- Albert Muñoz Vendrell
- Jaume Campdelacreu Fumado
- Dolors Dot Bach
- Isabel Fernández Conejero
- Elisabet Romero Gangonells
- Laura González Mera
- Maria Isabel Leon Moreno
- Raúl Domínguez Rubio
- Andres Julian Paipa Merchan
- Pablo Arroyo Pereiro
- Blanca Lara Rodríguez
- Velina Nedkova Hristova
POSTDOCTORAL RESEARCHERS
- Pol Andres Benito
PREDOCTORAL RESEARCHERS
- Silvia Muñoz Quiñones
- Carla Marco Cazcarra
- Sergio Roca Pereira
- Roser Gomez Llopico
- Yaiza Lopez Sampere
SCIENTIFIC SUPPORT
- Antonia Vinyals Rioseco
- Gisela Zamorano Garcia
- Sheila Álvarez Fornieles
- Yolanda Alonso Cumplido
- Laia Pallares Gayo
- Abdelilah Assialioui Essanhaji
MANAGEMENT SUPPORT
- José Luis Moreno Morejón
- Susana Pobla Müller
- Cristina Terrafeta Pastor
- Estela Montserrat Sanchez Machado
Neuroscience
Neuroscience
Scientific production
61
PAPERS
Average IF: 9,36
23
LED PAPERS
Average IF: 3,18
19 PUBLICATIONS IN FIRST DECILE
36 PUBLICATIONS IN FIRST QUARTILE
43 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Sarraj,A;Abraham,MG;Hassan,AE;Blackburn,S;Kasner,SE;Ortega Gutierrez,S;Hussain,MS et al, Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial., Lancet, 2024;403(10428):731-740, doi:10.1016/S0140-6736(24)00050-3
- Andrés Benito,P;Vázquez Costa,JF;Garzón,NCN;Colomina,MJ;Marco,C;González,L;Terrafeta,C et al, Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen, Int J Mol Sci, 2024;25(7):doi:10.3390/ijms25073810
- Arroyo Pereiro P, Muñoz-Vendrell A, León Moreno I, Bau L, Matas E, Romero-Pinel L, Martínez Yélamos A, Martínez Yélamos S, Andrés-Benito P. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort. J Neurol. 2024 Apr;271(4):1599-1609. doi: 10.1007/s00415-023-12135-w
- Naval Baudin,P;Pons Escoda,A;Castillo Pinar,A;Martínez Zalacain,I;Arroyo Pereiro,P;Flores Casaperalta,S;Garay Buitron,F et al, The T1-dark-rim: A novel imaging sign for detecting smoldering inflammation in multiple sclerosis, Eur J Radiol, 2024;173111358-111358, doi:10.1016/j.ejrad.2024.111358
- Roca Pereira,S;Domínguez,R;León,IM;Colomina,MJ;Yélamos,AM;Yélamos,SM;Povedano,M et al, Increased CXCL12, a potential CSF biomarker for differential diagnosis of amyotrophic lateral sclerosis, Brain Commun, 2024;6(4):doi:10.1093/braincomms/fcae271
Research highlights
PROJECTS
3 Granted competitive projects
5 Ongoing competitive projects
34 Started clinical trials
71 Ongoing clinical trials
PUBLISHED WORKS
1 Clinical guideline
1 Thesis
INNOVATION
1 Patent
1 License
NETWORKS
TRICALS
RETICS- REEM
CSUR
XUEC
ENCALS
ERN
Selected projects
- CPP2022-009778. NexTOLL: A Phase IIb Clinical trial to the evaluate neuroprotective effect of ApTOLL in stroke patients. Ministerio de Ciencia e Innovación. Budget: 485.715,5€. 2023-2026. PI: Cardona Portela, Pere.
- HNA. Caracterización de las vías moleculares subyacentes en el espectro patológico ELA-DFT en base a la expresión fenotípica: nuevos biomarcadores. FUNDACIÓN HNA. Budget: 87.780€. 2024-2026. PI: POVEDANO PANADES, MONICA.
- 2022-135-1. Red de ensayo secuencial de grupo, adaptativa y de multi-rama para evaluar la eficacia de fármacos en pacientes con Esclerosis Lateral Amiotrófica (ELA). STICHTING TRICALS FOUNDATION. Budget: 54.427,5€. 2022- . PI: MONICA POVEDANO PANADES.
- 2023-649-1. ESTUDIO DE FASE 3, DOBLE CIEGO, ALEATORIZADO, COMPARANDO LA EFICACIA Y SEGURIDAD DE FREXALIMAB (SAR441344) CON PLACEBO EN PARTICIPANTES ADULTOS CON ESCLEROSIS MÚLTIPLE SECUNDARIA PROGRESIVA SIN RECAÍDAS. Sanofi-Aventis, S.A.. Budget: 341.480€. 2024- . PI: Sergio Martínez Yélamos.
- 2023-443-1. THE PIVOTAL STUDY OF RAPIDPULSETM ASPIRATION SYSTEM AS FRONTLINE APPROACH FOR PATIENTS WITH ACUTE ISCHEMIC STROKE DUE TO LARGE VESSEL OCCLUSIONS (“RAPIDPULSE PIVOTAL STUDY”). RapidPulse, Inc. Budget: 266.900€. 2024- . PI: Pere Cardona Portela.